Literature DB >> 28420731

Distinct modulatory role of RNA in the aggregation of the tumor suppressor protein p53 core domain.

Petar Stefanov Kovachev1, Debapriya Banerjee1, Luciana Pereira Rangel2, Jonny Eriksson3, Murilo M Pedrote4, Mafalda Maria D C Martins-Dinis4, Katarina Edwards3, Yraima Cordeiro2, Jerson L Silva4, Suparna Sanyal5.   

Abstract

Inactivation of the tumor suppressor protein p53 by mutagenesis, chemical modification, protein-protein interaction, or aggregation has been associated with different human cancers. Although DNA is the typical substrate of p53, numerous studies have reported p53 interactions with RNA. Here, we have examined the effects of RNA of varied sequence, length, and origin on the mechanism of aggregation of the core domain of p53 (p53C) using light scattering, intrinsic fluorescence, transmission electron microscopy, thioflavin-T binding, seeding, and immunoblot assays. Our results are the first to demonstrate that RNA can modulate the aggregation of p53C and full-length p53. We found bimodal behavior of RNA in p53C aggregation. A low RNA:protein ratio (∼1:50) facilitates the accumulation of large amorphous aggregates of p53C. By contrast, at a high RNA:protein ratio (≥1:8), the amorphous aggregation of p53C is clearly suppressed. Instead, amyloid p53C oligomers are formed that can act as seeds nucleating de novo aggregation of p53C. We propose that structured RNAs prevent p53C aggregation through surface interaction and play a significant role in the regulation of the tumor suppressor protein.
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  RNA; amyloid; domain V of 23S rRNA; fluorescence; kinetics; p53; p53C; prion; protein aggregation; protein folding

Mesh:

Substances:

Year:  2017        PMID: 28420731      PMCID: PMC5454114          DOI: 10.1074/jbc.M116.762096

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  69 in total

1.  The ins and outs of p53.

Authors:  K H Vousden; G F Vande Woude
Journal:  Nat Cell Biol       Date:  2000-10       Impact factor: 28.824

2.  Conversion of wild-type p53 core domain into a conformation that mimics a hot-spot mutant.

Authors:  Daniella Ishimaru; Lenize F Maia; Larissa M Maiolino; Pablo A Quesado; Priscila C M Lopez; Fabio C L Almeida; Ana Paula Valente; Jerson L Silva
Journal:  J Mol Biol       Date:  2003-10-17       Impact factor: 5.469

3.  Nanoparticles as catalysts for protein fibrillation.

Authors:  Vicki L Colvin; Kristen M Kulinowski
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-14       Impact factor: 11.205

Review 4.  Fluorescence as a method to reveal structures and membrane-interactions of amyloidogenic proteins.

Authors:  Larissa A Munishkina; Anthony L Fink
Journal:  Biochim Biophys Acta       Date:  2007-03-28

Review 5.  Intriguing nucleic-acid-binding features of mammalian prion protein.

Authors:  Jerson L Silva; Luís Maurício T R Lima; Debora Foguel; Yraima Cordeiro
Journal:  Trends Biochem Sci       Date:  2008-02-19       Impact factor: 13.807

6.  Cognate DNA stabilizes the tumor suppressor p53 and prevents misfolding and aggregation.

Authors:  Daniella Ishimaru; Ana Paula D Ano Bom; Luís Maurício T R Lima; Pablo A Quesado; Marcos F C Oyama; Claudia V de Moura Gallo; Yraima Cordeiro; Jerson L Silva
Journal:  Biochemistry       Date:  2009-07-07       Impact factor: 3.162

7.  Refolding of denatured lactate dehydrogenase by Escherichia coli ribosomes.

Authors:  S Chattopadhyay; B Das; A K Bera; D Dasgupta; C Dasgupta
Journal:  Biochem J       Date:  1994-06-15       Impact factor: 3.857

8.  Δ113p53/Δ133p53 converts P53 from a repressor to a promoter of DNA double-stand break repair.

Authors:  Lu Gong; Jun Chen
Journal:  Mol Cell Oncol       Date:  2015-05-27

9.  Negative feedback regulation of wild-type p53 biosynthesis.

Authors:  J Mosner; T Mummenbrauer; C Bauer; G Sczakiel; F Grosse; W Deppert
Journal:  EMBO J       Date:  1995-09-15       Impact factor: 11.598

10.  Protein folding activity of ribosomal RNA is a selective target of two unrelated antiprion drugs.

Authors:  Déborah Tribouillard-Tanvier; Suzana Dos Reis; Fabienne Gug; Cécile Voisset; Vincent Béringue; Raimon Sabate; Ema Kikovska; Nicolas Talarek; Stéphane Bach; Chenhui Huang; Nathalie Desban; Sven J Saupe; Surachai Supattapone; Jean-Yves Thuret; Stéphane Chédin; Didier Vilette; Hervé Galons; Suparna Sanyal; Marc Blondel
Journal:  PLoS One       Date:  2008-05-14       Impact factor: 3.240

View more
  20 in total

1.  DNA Facilitates Oligomerization and Prevents Aggregation via DNA Networks.

Authors:  Theodore J Litberg; Brianne Docter; Michael P Hughes; Jennifer Bourne; Scott Horowitz
Journal:  Biophys J       Date:  2019-11-23       Impact factor: 4.033

Review 2.  Salvation of the fallen angel: Reactivating mutant p53.

Authors:  Yang Li; Zhuoyi Wang; Yuchen Chen; Robert B Petersen; Ling Zheng; Kun Huang
Journal:  Br J Pharmacol       Date:  2019-02-28       Impact factor: 8.739

Review 3.  p53 Isoforms as Cancer Biomarkers and Therapeutic Targets.

Authors:  Liuqun Zhao; Suparna Sanyal
Journal:  Cancers (Basel)       Date:  2022-06-27       Impact factor: 6.575

4.  Harnessing an RNA-mediated chaperone for the assembly of influenza hemagglutinin in an immunologically relevant conformation.

Authors:  Seung Won Yang; Yo Han Jang; Soon Bin Kwon; Yoon Jae Lee; Wonil Chae; Young Ho Byun; Paul Kim; Chan Park; Young Jae Lee; Choon Kang Kim; Young Seok Kim; Seong Il Choi; Baik Lin Seong
Journal:  FASEB J       Date:  2018-01-02       Impact factor: 5.191

5.  A quantitative characterization of interaction between prion protein with nucleic acids.

Authors:  Alakesh Bera; Sajal Biring
Journal:  Biochem Biophys Rep       Date:  2018-05-02

Review 6.  40 Years of Research Put p53 in Translation.

Authors:  Virginie Marcel; Flora Nguyen Van Long; Jean-Jacques Diaz
Journal:  Cancers (Basel)       Date:  2018-05-21       Impact factor: 6.639

7.  Aggregation-primed molten globule conformers of the p53 core domain provide potential tools for studying p53C aggregation in cancer.

Authors:  Murilo M Pedrote; Guilherme A P de Oliveira; Adriani L Felix; Michelle F Mota; Mayra de A Marques; Iaci N Soares; Anwar Iqbal; Douglas R Norberto; Andre M O Gomes; Enrico Gratton; Elio A Cino; Jerson L Silva
Journal:  J Biol Chem       Date:  2018-05-31       Impact factor: 5.157

8.  Loss of the p53 transactivation domain results in high amyloid aggregation of the Δ40p53 isoform in endometrial carcinoma cells.

Authors:  Nataly Melo Dos Santos; Guilherme A P de Oliveira; Murilo Ramos Rocha; Murilo M Pedrote; Giulia Diniz da Silva Ferretti; Luciana Pereira Rangel; José A Morgado-Diaz; Jerson L Silva; Etel Rodrigues Pereira Gimba
Journal:  J Biol Chem       Date:  2019-04-26       Impact factor: 5.157

9.  RNA modulates aggregation of the recombinant mammalian prion protein by direct interaction.

Authors:  Petar Stefanov Kovachev; Mariana P B Gomes; Yraima Cordeiro; Natália C Ferreira; Leticia P Felix Valadão; Lucas M Ascari; Luciana P Rangel; Jerson L Silva; Suparna Sanyal
Journal:  Sci Rep       Date:  2019-08-27       Impact factor: 4.379

Review 10.  p53 Isoforms and Their Implications in Cancer.

Authors:  Maximilian Vieler; Suparna Sanyal
Journal:  Cancers (Basel)       Date:  2018-08-25       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.